Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses findings from a Phase II trial (NCT05190445) of cinrebafusp alfa, a bispecific fusion protein targeting HER2 and 4-1BB, in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma. The investigational drug was administered with ramucirumab and paclitaxel, and was well tolerated in patients, where a manageable safety profile was reported. All patients additionally achieved a partial response rate. This interview took place at the American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.